Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Gabriel Chodick, Sarah Sharman Moser & Inbal Goldshtein. (2016) Non-adherence with bisphosphonates among patients with osteoporosis: impact on fracture risk and healthcare cost. Expert Review of Pharmacoeconomics & Outcomes Research 16:3, pages 359-370.
Read now
Read now
Mir Sadat-Ali, Bader Al-Shafie, Abdallah S Al-Omran & Mohammed Q Azam. (2012) Medication burden of Saudi Arabian women receiving antiresorptive therapy. International Journal of Women's Health 4, pages 433-436.
Read now
Read now
Chris Recknor. (2011) Zoledronic acid for prevention and treatment of osteoporosis. Expert Opinion on Pharmacotherapy 12:5, pages 807-815.
Read now
Read now
Raymond E. Cole. (2011) Clinical Strategies to Address Patients' Concerns in Osteoporosis Management with Bisphosphonates. Postgraduate Medicine 123:2, pages 131-144.
Read now
Read now
John A Sunyecz. (2010) Zoledronic acid infusion for prevention and treatment of osteoporosis. International Journal of Women's Health 2, pages 353-360.
Read now
Read now
Véronique Rabenda & Jean-Yves Reginster. (2010) Overcoming problems with adherence to osteoporosis medication. Expert Review of Pharmacoeconomics & Outcomes Research 10:6, pages 677-689.
Read now
Read now
Kristina Casadei & Carolyn Becker. (2009) Once-monthly risedronate for postmenopausal osteoporosis. International Journal of Women's Health 1, pages 1-9.
Read now
Read now
Deborah T. Gold, Haian Trinh & Wael Safi. (2009) Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. Current Medical Research and Opinion 25:8, pages 1831-1839.
Read now
Read now
John Sunyecz. (2008) Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations. Clinical Interventions in Aging 3:4, pages 611-627.
Read now
Read now
Colleen A. McHorney, John T. Schousboe, Richard R. Cline & Thomas W. Weiss. (2007) The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Current Medical Research and Opinion 23:12, pages 3137-3152.
Read now
Read now
Articles from other publishers (28)
Ekaterina N. Dudinskaya, Natalia M. Vorobyeva, Julia S. Onuchina, Lubov V. Machekhina, Elena V. Selezneva, Lilia N. Ovcharova, Yulia V. Kotovskaya & Olga N. Tkacheva. (2023) The association of osteoporosis and geriatric syndromes in the elderly: data from the Russian epidemiological study EVKALIPT. Archives of Osteoporosis 18:1.
Crossref
Crossref
Faisal I. Almohaileb & Zafar Rasheed. (2022) Comparing the Efficacies of Bisphosphonates’ Therapies for Osteoporosis Persistence and Compliance: A Systematic Review. Current Molecular Medicine 22:3, pages 274-284.
Crossref
Crossref
Hyunil Lee, Sangcheol Lee, Dokyung Kim, Weonmin Cho, Sungtan Cho, Siyeong Yoon & Soonchul Lee. (2021) Effect of Dosing Interval on Compliance of Osteoporosis Patients on Bisphosphonate Therapy: Observational Study Using Nationwide Insurance Claims Data. Journal of Clinical Medicine 10:19, pages 4350.
Crossref
Crossref
Deborah T. Gold. 2021. Marcus and Feldman's Osteoporosis. Marcus and Feldman's Osteoporosis
1695
1707
.
Yu-Ciou Lin, Tien-Ching Lee, Chung-Yu Chen, Shun-Jin Lin, Shang-Jyh Hwang & Ming-Yen Lin. (2020) Effectiveness of antiresorptive medications in women on long-term dialysis after hip fracture: A population-based cohort study. PLOS ONE 15:9, pages e0238248.
Crossref
Crossref
Patrice Fardellone, Stefano Lello, Antonio Cano, Eloisa de Sá Moreira, Renato Watanabe de Oliveira, Guilherme Silva Julian & Boxiong Tang. (2019) Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review. Clinical Therapeutics 41:8, pages 1576-1588.
Crossref
Crossref
C. T. Yeam, S. Chia, H. C. C. Tan, Y. H. Kwan, W. Fong & J. J. B. Seng. (2018) A systematic review of factors affecting medication adherence among patients with osteoporosis. Osteoporosis International 29:12, pages 2623-2637.
Crossref
Crossref
Hideaki Kishimoto & Masayuki Maehara. (2015) Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Archives of Osteoporosis 10:1.
Crossref
Crossref
L. Karlsson, J. Lundkvist, E. Psachoulia, M. Intorcia & O. Ström. (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporosis International 26:10, pages 2401-2411.
Crossref
Crossref
John T. Schousboe. 2013. Osteoporosis. Osteoporosis
239
262
.
Job F. M. van Boven, Pieter T. de Boer, Maarten J. Postma & Stefan Vegter. (2013) Persistence with osteoporosis medication among newly-treated osteoporotic patients. Journal of Bone and Mineral Metabolism 31:5, pages 562-570.
Crossref
Crossref
John T. Schousboe. (2013) Adherence with Medications Used to Treat Osteoporosis: Behavioral Insights. Current Osteoporosis Reports 11:1, pages 21-29.
Crossref
Crossref
Joseph Borrelli. (2012) Taking Control: The Osteoporosis Epidemic. Injury 43:8, pages 1235-1236.
Crossref
Crossref
Cyrille B Confavreux, Florence Canoui-Poitrine, Anne-Marie Schott, Véronique Ambrosi, Valérie Tainturier & Roland D Chapurlat. (2012) Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database. European Journal of Endocrinology 166:4, pages 735-741.
Crossref
Crossref
J. Devine, S. Trice, Z. Finney, S. Yarger, E. Nwokeji, A. Linton & W. Davies. (2011) A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System. Osteoporosis International 23:4, pages 1415-1424.
Crossref
Crossref
Matti S. Aapro & Robert E. Coleman. (2012) Bone health management in patients with breast cancer: Current standards and emerging strategies. The Breast 21:1, pages 8-19.
Crossref
Crossref
Peyman Hadji, Michael Gnant, Matti Aapro, Allan Lipton & Robert Coleman. (2011) Dosing of zoledronic acid throughout the treatment continuum in breast cancer. Critical Reviews in Oncology/Hematology 79:2, pages 175-188.
Crossref
Crossref
J. C. Netelenbos, P. P. Geusens, G. Ypma & S. J. E. Buijs. (2010) Adherence and profile of non-persistence in patients treated for osteoporosis—a large-scale, long-term retrospective study in The Netherlands. Osteoporosis International 22:5, pages 1537-1546.
Crossref
Crossref
S. Lee, P. Glendenning & C. A. Inderjeeth. (2010) Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Osteoporosis International 22:3, pages 741-753.
Crossref
Crossref
Becky A. Briesacher, Susan E. Andrade, Leslie R. Harrold, Hassan Fouayzi & Robert A. Yood. (2010) Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates. Pharmacoepidemiology and Drug Safety 19:12, pages 1233-1240.
Crossref
Crossref
I. Imaz, P. Zegarra, J. González-Enríquez, B. Rubio, R. Alcazar & J. M. Amate. (2009) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporosis International 21:11, pages 1943-1951.
Crossref
Crossref
Becky A. Briesacher, Susan E. Andrade, Leslie R. Harrold, Hassan Fouayzi & Robert A. Yood. (2010) Adoption of Once-monthly Oral Bisphosphonates and the Impact on Adherence. The American Journal of Medicine 123:3, pages 275-280.
Crossref
Crossref
Bart L. Clarke. (2009) New and emerging treatments for osteoporosis. Clinical Endocrinology 71:3, pages 309-321.
Crossref
Crossref
Felicia Cosman. (2009) Treatment of Osteoporosis and Prevention of New Fractures: Role of Intravenously Administered Bisphosphonates. Endocrine Practice 15:5, pages 483-493.
Crossref
Crossref
Jean-Yves ReginsterMickaël HiligsmannVéronique RabendaBrigitte ZegelsAudrey NeuprezOlivier Bruyere. (2009) Ibandronate in the Management of Postmenopausal Osteoporosis. Clinical Medicine. Therapeutics 1, pages CMT.S2354.
Crossref
Crossref
Kurt Lippuner, Albrecht Popp, Thomas Szucs & Matthias Schwenkglenks. (2013) Kosteneffektivität einer Osteoporose-Behandlung nach systematischem Bevölkerungsscreening in der Schweiz: Auswirkungen der Preisreduktion des Alendronat-OriginalpräparatesCost-effectiveness of osteoporosis treatment following systematic population screening in Switzerland: Impact of the price reduction of the original brand of alendronate. PharmacoEconomics German Research Articles 6:1, pages 19-28.
Crossref
Crossref
E. Michael Lewiecki, Ann M. Babbitt, Veronica K. Piziak, Zafer E. Ozturk & Henry G. Bone. (2008) Adherence to and Gastrointestinal Tolerability of Monthly Oral or Quarterly Intravenous Ibandronate Therapy in Women with Previous Intolerance to Oral Bisphosphonates: A 12-Month, Open-Label, Prospective Evaluation. Clinical Therapeutics 30:4, pages 605-621.
Crossref
Crossref
Stuart L. Silverman & Deborah T. Gold. (2008) Compliance and persistence with osteoporosis therapies. Current Rheumatology Reports 10:2, pages 118-122.
Crossref
Crossref